e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Enveda
Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead Metabolic Disease Strategy
December 17, 2025
From
Enveda
Via
Business Wire
Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma
December 09, 2025
From
Enveda
Via
Business Wire
Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors
September 04, 2025
From
Enveda
Via
Business Wire
Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis
May 28, 2025
From
Enveda
Via
Business Wire
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
February 26, 2025
From
Enveda
Via
Business Wire
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
February 05, 2025
From
Enveda
Via
Business Wire
Enveda Welcomes Jason Kim as Chief Financial Officer
January 10, 2025
From
Enveda
Via
Business Wire
Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates
November 21, 2024
From
Enveda
Via
Business Wire
Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials
November 13, 2024
From
Enveda
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.